News Sanofi, Orano cue up filings for GEP-NET radioligand therapy Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.
News Sanofi faces EU antitrust probe into vaccine business Sanofi has confirmed it is being investigated by the European Commission for potentially anticompetitive activity in its vaccines business.
News AZ halts UK investment, and Lilly, Sanofi follow suit After MSD's bombshell retreat from a big UK investment plan, AstraZeneca, Lilly, and Sanofi are also pressing pause on new projects.
News Sanofi slumps despite positive eczema drug readout Shares in Sanofi have fallen after it reported data from a phase 3 trial of atopic dermatitis drug amlitelimab – even though it met all objectives.
News Sanofi breaks new ground for BTK drugs with ITP approval Sanofi's BTK inhibitor Wayrilz has become the first drug in the class to be approved for rare platelet-busting disease immune thrombocytopenia.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.